Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Deerfield Management Company
Deal Size : $67.0 million
Deal Type : Series A Financing
Details : The two technology platforms have unique capabilities to simultaneously engineer AAV capsids to exhibit enhanced cellular tropism, evasion of pre-existing immunity, while maintaining and potentially improving manufacturability.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 26, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Deerfield Management Company
Deal Size : $67.0 million
Deal Type : Series A Financing